The in-vitro activity of ofloxacin, a new quinolone derivative, was evaluated in 273 bacterial strains isolated from urine. The results showed a remarkable activity against most Gram-negative bacteria and, in particular, against Enterobacter aerogenes, which is very difficult to eradicate even with third-generation cephalosporins.